Immix Biopharma, Inc. 4

Director-level insider Carey Ng received 6,250 RSUs and a 12,500-share stock option award in Immix Biopharma, Inc. common stock as equity compensation on May 22, 2026.

On May 22, 2026, reporting person Carey Ng received an equity compensation package from Immix Biopharma, Inc. consisting of 6,250 restricted stock units of common stock and a stock option for 12,500 shares at an exercise price of $8.78 per share, granted under the issuer’s 2021 Equity Incentive Plan. The RSUs will vest in full on the earlier of the one-year anniversary of grant or the date of the company’s 2027 annual shareholders’ meeting, subject to continued service, while the option will vest in substantially equal monthly installments over 12 months (or accelerate at the 2027 annual meeting if earlier), contingent on continued board service. Following these awards, Ng holds 26,250 shares of common stock directly and an additional 1,025,221 shares are reported as indirectly owned through Mesa Verde Venture Partners III, LP, for which he serves as Managing Director and disclaims beneficial ownership beyond his pecuniary interest, and he also holds 12,500 stock options not yet exercised.

Filing Facts

CIK

1873835

Ticker

IMMX

Form

4

Source Type

sec

Accession

0001493152-26-026430

Alert Tier

5